Scarica l'app Stockscreener
1.73
7.98%
-0.15
Dopo l'orario di chiusura:
1.75
0.02
+1.16%
Precedente Chiudi:
$1.88
Aprire:
$1.87
Volume 24 ore:
887.22K
Relative Volume:
2.57
Capitalizzazione di mercato:
$86.78M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-21.72%
1M Prestazione:
+0.00%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$1.68
$1.87
Intervallo di 1 settimana:
$1.42
$2.26
Portata 52W:
$1.42
$2.30
Mindwalk Holdings Corp Stock (HYFT) Company Profile
Nome
Mindwalk Holdings Corp
Settore
Industria
Telefono
-
Indirizzo
-
Confronta HYFT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HYFT
Mindwalk Holdings Corp
|
1.73 | 86.78M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.12 | 99.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.99 | 63.46B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.56 | 59.27B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
736.76 | 44.78B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
334.40 | 37.75B | 3.81B | -644.79M | -669.77M | -6.24 |
Mindwalk Holdings Corp Stock (HYFT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-12-02 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-25 | Iniziato | The Benchmark Company | Buy |
Mindwalk Holdings Corp Borsa (HYFT) Ultime notizie
MindWalk : Accelerating Drug Discovery through First End-to-End Bio-Native AI Platform - MarketScreener
How MindWalk Holdings' Rebranding and Improved Earnings May Impact HYFT Investors - Yahoo Finance
MindWalk Holdings Reports Strong Revenue Growth and Improved Margins - TipRanks
MindWalk Holdings Corp (HYFT) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic ... - Yahoo Finance
MindWalk Holdings Corp (HYFT) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Rebranding - GuruFocus
MindWalk Holdings Reports Q3 2025 Financial Results and Strategic Growth - TipRanks
MindWalk Holdings Corp reports results for the quarter ended July 31Earnings Summary - TradingView
MindWalk Holdings Reports Record Revenue and Strategic Divestiture - TipRanks
MindWalk Holdings Corp. Reports Earnings Results for the First Quarter Ended July 31, 2025 - MarketScreener
MindWalk Holdings Corp.™ (formerly ImmunoPrecise Antibodies™) Reports Record $7.6 Million Quarterly - PharmiWeb.com
Earnings call transcript: MindWalk Inc. reports strong Q1 2025 performance, rebrands from ImmunoPrecise Antibodies - Investing.com UK
MindWalk Holdings Corp. (HYFT) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
MindWalk Holdings Corp.™ (formerly ImmunoPrecise Antibodies™) Reports Record $7.6 Million Quarterly Revenue, 45% Growth, Margin Expansion, Narrowed Losses, and Strengthened Balance Sheet - Business Wire
MindWalk : 2025 Combined Financial Statements - MarketScreener
MindWalk to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2026 on September 15, 2025 - Business Wire
MindWalk Holdings Corp. (HYFT) - Zacks Investment Research
HYFT Stock Price and Chart — NASDAQ:HYFT - TradingView
ImmunoPrecise Antibodies rebrands as MindWalk, changes ticker to HYFT By Investing.com - Investing.com Canada
HYFT's Rebranding: A Strategic Pivot in Biotech's AI-Driven Future - AInvest
ImmunoPrecise Antibodies rebrands as MindWalk, changes ticker to HYFT - Investing.com
Immunoprecise rebrands as Mindwalk, announces Nasdaq ticker change to "HYFT" - MarketScreener
ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to “HYFT” - FinancialContent
ImmunoPrecise Antibodies Ltd. has Changed its Name to MindWalk - MarketScreener
ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate Bio-Native AI Innovation - Business Wire
ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA - Business Wire
™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic - Business Wire
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025 - MarketScreener
ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors - MarketScreener
Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data - Business Wire
AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies - Business Wire
ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery - Business Wire
IPA's LENSai Platform Delivers X-Ray-Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed - MarketScreener
ImmunoPrecise Antibodies Ltd.'s Lensai?? Platform Delivers X-Ray-Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed - MarketScreener
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 - MarketScreener
ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics. - Business Wire
IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025 - MarketScreener
IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025 - MarketScreener
ImmunoPrecise Antibodies Announces Key Leadership Changes - MarketScreener
Trump's "Stargate AI" Healthcare/Medical Watch: CSDX, IPA, MGX, CDIO - MarketScreener
IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment - MarketScreener
IPA Announces Resignation of Chief Financial Officer - MarketScreener
MindWalk Holdings Corp. (HYFT) Q2 FY2025 earnings call transcript - Yahoo Finance
ImmunoPrecise to Host TECHDAY: Cutting Edge AI and Biologics Innovation Form 6 K - MarketScreener
Immunoprecise Antibodies Successfully Engineers in Silico Antibodies to Elusive Tumor Protein Using Its Patented LENSai Technology - MarketScreener
Immunoprecise Antibodies Ltd. Announces the Commercial Release of Lens Ai API, Hereafter Referred to as the `Software', by Its Subsidiary, Biostrand - MarketScreener
ImmunoPrecise Antibodies Ltd. Announces an Expansion of Its LENSai Platform - MarketScreener
ImmunoPrecise Antibodies Develops the Lensai's Integrated Intelligence Platform Powered by Hyft Technology - MarketScreener
Mindwalk Holdings Corp Azioni (HYFT) Dati Finanziari
Non sono disponibili dati finanziari per Mindwalk Holdings Corp (HYFT). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.43%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):